What prompted Hims & Hers to raise its annual revenue forecast?

Hims & Hers raised its full-year revenue guidance to $3.1 billion–$3.3 billion from $2.8 billion–$3.0 billion due to strong subscriber growth driven by its strategic pivot to FDA-approved treatments—particularly Novo Nordisk’s Wegovy—after shifting away from lower-cost compounded GLP-1 drugs and securing a partnership with Novo Nordisk in March following the FDA’s restriction of copycat weight-loss drugs.

How did Hims & Hers’ revenue performance in the latest quarter compare to expectations and prior year?

Hims reported quarterly revenue of $753 million, surpassing both the prior year’s $544 million and analysts’ expectation of $699.89 million, as compiled by LSEG.

Hims & Hers Raises Annual Revenue Forecast on Strong Subscriber Growth

Aug 10, 2026

Hims & Hers raised its full-year revenue guidance to $3.1–$3.3 billion after reporting $753 million in quarterly revenue. The growth was driven by a partnership with Novo Nordisk to offer the FDA-approved weight-loss drug Wegovy on its platform.

reuters

2026-05-11

Hims & Hers Misses Revenue Estimates as Strategy Shift Hits Sales

2026-08-10

Hims & Hers Raises Annual Revenue Forecast on Strong Subscriber Growth

Hims & Hers Raises Annual Revenue Forecast on Strong Subscriber Growth

FAQ